Hatteras Venture Partners, a Durham, NC-based venture capital firm , with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine, has held the first close of Hatteras Venture Partners IV at $74m.
With HVP IV, whose final target is at $125m, Hatteras has formally launched “Hatteras Discovery”, an up to 20% allocation of the fund dedicated to investing in seed stage companies and projects in the field of human medicine and life sciences. This project will be led by Christy Shaffer, PhD, the former CEO of Inspire Pharmaceuticals, who as joined Hatteras as the Managing Director of Hatteras Discovery and a Venture Partner.
Led by General Partner Bob Ingram, Hatteras will invest funds from HVP IV focusing on the active involvement of its team of seasoned entrepreneurs and operators. In addition, HVP IV will leverage its strategic relationships with major companies in the health care field, many of which are limited partners in the fund.
The firm has also added Myla Lai Goldman, MD, former Chief Medical Officer and Chief Science Officer of LabCorp, and Fred Goldwater, former SVP of Strategic Development and CIO for Blue Cross Blue Shield of NC, as Venture Partners.
In addition, Mike Dial, Ph.D., an Analyst with the firm, has been promoted to Associate.